Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Eloralintide

Eloralintide

Amylin · s.c. · Eli Lilly

Data cut 12 November 2026 · page built 16 November 2026 · 3 trial arms · 1 trials with results · 6 registered trials · see on the pipeline board

Summary

Also known as
LY3841136
Mechanism
Amylin
Route
s.c.
Company
Eli Lilly
Highest development stage
phase 3
Status (as of data cut)
Phase 3 ENLIGHTEN programme recruiting since Dec 2025 (obesity, T2D, sleep apnoea, knee osteoarthritis, maintenance after incretin therapy); phase 2 complete verify
Next milestone
ENLIGHTEN phase 3 results

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity2 phase 3 ongoingPhase 3 ongoing
T2D2 phase 3 ongoingPhase 3 ongoing
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea2 phase 3 ongoingPhase 3 ongoing
Knee OA2 phase 3 ongoingPhase 3 ongoing
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
EloraTZP phase 2b (obesity + T2D)eloralintide 3 mgt2d48—−8.2 % vs −3.0 %
Δ −5.2 pp
—−1.1 vs −0.3——————press release
EloraTZP phase 2b (obesity + T2D)eloralintide 6 mgt2d48—−12.3 % vs −3.0 %
Δ −9.3 pp
—−1.4 vs −0.3——————press release
EloraTZP phase 2b (obesity + T2D)eloralintide 9 mgt2d48—−11.1 % vs −3.0 %
Δ −8.1 pp
—−1.3 vs −0.3——————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (3)
  • eloralintide 3 mg · weight_eff · press release table
    Elora 3 mg -8.2 %
  • eloralintide 6 mg · weight_eff · press release table
    Elora 6 mg -12.3 %
  • eloralintide 9 mg · weight_eff · press release table
    Elora 9 mg -11.1 %

Registered trials (6)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
ENLIGHTEN-10
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
ObesityPhase 3not yet recruiting2026-12 → 2029-113000not yet recruitingNCT07900633
ENLIGHTEN-1
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
ObesityPhase 3recruiting2026-02 → 2028-031980recruitingNCT07321886
ENLIGHTEN-4
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Knee OAPhase 3recruiting2026-02 → 2028-03900recruitingNCT07353931
ENLIGHTEN-3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Sleep apnoeaPhase 3recruiting2026-02 → 2028-03800recruitingNCT07369011
ENLIGHTEN-6
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
ObesityPhase 3recruiting2026-02 → 2028-06900recruitingNCT07392190
ENLIGHTEN-2
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
ObesityPhase 3recruiting2025-12 → 2028-011035recruitingNCT07282600

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Eloralintide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/eloralintide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.